|
Gene: NT5C3B |
Gene summary for NT5C3B |
Gene summary. |
Gene information | Species | Human | Gene symbol | NT5C3B | Gene ID | 115024 |
Gene name | 5'-nucleotidase, cytosolic IIIB | |
Gene Alias | NT5C3L | |
Cytomap | 17q21.2 | |
Gene Type | protein-coding | GO ID | GO:0000288 | UniProtAcc | Q969T7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
115024 | NT5C3B | LZE2T | Human | Esophagus | ESCC | 4.45e-03 | 7.31e-01 | 0.082 |
115024 | NT5C3B | LZE4T | Human | Esophagus | ESCC | 8.64e-17 | 4.06e-01 | 0.0811 |
115024 | NT5C3B | LZE8T | Human | Esophagus | ESCC | 1.39e-02 | 4.25e-02 | 0.067 |
115024 | NT5C3B | LZE20T | Human | Esophagus | ESCC | 4.95e-02 | 2.86e-02 | 0.0662 |
115024 | NT5C3B | LZE22D1 | Human | Esophagus | HGIN | 4.95e-04 | 1.13e-01 | 0.0595 |
115024 | NT5C3B | LZE24T | Human | Esophagus | ESCC | 9.36e-16 | 4.84e-01 | 0.0596 |
115024 | NT5C3B | P1T-E | Human | Esophagus | ESCC | 5.28e-03 | 3.86e-01 | 0.0875 |
115024 | NT5C3B | P2T-E | Human | Esophagus | ESCC | 1.08e-35 | 7.01e-01 | 0.1177 |
115024 | NT5C3B | P4T-E | Human | Esophagus | ESCC | 2.92e-34 | 9.38e-01 | 0.1323 |
115024 | NT5C3B | P5T-E | Human | Esophagus | ESCC | 9.69e-39 | 9.09e-01 | 0.1327 |
115024 | NT5C3B | P8T-E | Human | Esophagus | ESCC | 7.00e-33 | 5.46e-01 | 0.0889 |
115024 | NT5C3B | P9T-E | Human | Esophagus | ESCC | 9.23e-21 | 6.00e-01 | 0.1131 |
115024 | NT5C3B | P10T-E | Human | Esophagus | ESCC | 3.18e-22 | 4.28e-01 | 0.116 |
115024 | NT5C3B | P11T-E | Human | Esophagus | ESCC | 4.14e-17 | 9.91e-01 | 0.1426 |
115024 | NT5C3B | P12T-E | Human | Esophagus | ESCC | 2.51e-59 | 1.12e+00 | 0.1122 |
115024 | NT5C3B | P15T-E | Human | Esophagus | ESCC | 8.72e-29 | 7.90e-01 | 0.1149 |
115024 | NT5C3B | P16T-E | Human | Esophagus | ESCC | 1.46e-36 | 7.78e-01 | 0.1153 |
115024 | NT5C3B | P17T-E | Human | Esophagus | ESCC | 6.77e-05 | 4.10e-01 | 0.1278 |
115024 | NT5C3B | P19T-E | Human | Esophagus | ESCC | 3.35e-10 | 9.51e-01 | 0.1662 |
115024 | NT5C3B | P20T-E | Human | Esophagus | ESCC | 5.32e-31 | 8.96e-01 | 0.1124 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0044270110 | Skin | cSCC | cellular nitrogen compound catabolic process | 179/4864 | 451/18723 | 8.34e-11 | 3.79e-09 | 179 |
GO:0019439110 | Skin | cSCC | aromatic compound catabolic process | 183/4864 | 467/18723 | 1.76e-10 | 7.68e-09 | 183 |
GO:0000956110 | Skin | cSCC | nuclear-transcribed mRNA catabolic process | 59/4864 | 112/18723 | 1.46e-09 | 5.60e-08 | 59 |
GO:0061013110 | Skin | cSCC | regulation of mRNA catabolic process | 79/4864 | 166/18723 | 1.57e-09 | 5.92e-08 | 79 |
GO:1901361110 | Skin | cSCC | organic cyclic compound catabolic process | 188/4864 | 495/18723 | 1.92e-09 | 7.01e-08 | 188 |
GO:0043487110 | Skin | cSCC | regulation of RNA stability | 80/4864 | 170/18723 | 2.39e-09 | 8.52e-08 | 80 |
GO:004348824 | Skin | cSCC | regulation of mRNA stability | 75/4864 | 158/18723 | 4.64e-09 | 1.55e-07 | 75 |
GO:006115718 | Skin | cSCC | mRNA destabilization | 44/4864 | 84/18723 | 2.14e-07 | 4.60e-06 | 44 |
GO:006101418 | Skin | cSCC | positive regulation of mRNA catabolic process | 45/4864 | 87/18723 | 2.53e-07 | 5.29e-06 | 45 |
GO:005077918 | Skin | cSCC | RNA destabilization | 44/4864 | 88/18723 | 1.16e-06 | 2.03e-05 | 44 |
GO:000675324 | Skin | cSCC | nucleoside phosphate metabolic process | 176/4864 | 497/18723 | 1.55e-06 | 2.62e-05 | 176 |
GO:000911724 | Skin | cSCC | nucleotide metabolic process | 173/4864 | 489/18723 | 2.03e-06 | 3.35e-05 | 173 |
GO:003424915 | Skin | cSCC | negative regulation of cellular amide metabolic process | 104/4864 | 273/18723 | 6.44e-06 | 9.00e-05 | 104 |
GO:001714814 | Skin | cSCC | negative regulation of translation | 93/4864 | 245/18723 | 2.28e-05 | 2.63e-04 | 93 |
GO:000028818 | Skin | cSCC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 29/4864 | 56/18723 | 3.25e-05 | 3.56e-04 | 29 |
GO:00002914 | Skin | cSCC | nuclear-transcribed mRNA catabolic process, exonucleolytic | 13/4864 | 19/18723 | 1.27e-04 | 1.16e-03 | 13 |
GO:00439284 | Skin | cSCC | exonucleolytic catabolism of deadenylated mRNA | 10/4864 | 13/18723 | 1.78e-04 | 1.50e-03 | 10 |
GO:001631115 | Skin | cSCC | dephosphorylation | 134/4864 | 417/18723 | 2.65e-03 | 1.50e-02 | 134 |
GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024021 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024031 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NT5C3B | SNV | Missense_Mutation | rs781909203 | c.310N>C | p.Glu104Gln | p.E104Q | Q969T7 | protein_coding | deleterious(0.02) | benign(0.03) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NT5C3B | SNV | Missense_Mutation | c.310G>A | p.Glu104Lys | p.E104K | Q969T7 | protein_coding | deleterious(0.01) | benign(0.031) | TCGA-B6-A2IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
NT5C3B | insertion | Nonsense_Mutation | novel | c.270_271insTGGTGTTCTTCATGGTGACTGGGAGTTGGCT | p.Pro91TrpfsTer6 | p.P91Wfs*6 | Q969T7 | protein_coding | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
NT5C3B | SNV | Missense_Mutation | c.164N>A | p.Arg55Gln | p.R55Q | Q969T7 | protein_coding | deleterious(0.02) | possibly_damaging(0.624) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
NT5C3B | SNV | Missense_Mutation | c.634N>C | p.Asn212His | p.N212H | Q969T7 | protein_coding | tolerated(0.21) | benign(0.006) | TCGA-CM-6169-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Ancillary | leucovorin | SD | |
NT5C3B | SNV | Missense_Mutation | c.662N>A | p.Gly221Asp | p.G221D | Q969T7 | protein_coding | tolerated(1) | benign(0.241) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NT5C3B | SNV | Missense_Mutation | novel | c.737A>G | p.Asn246Ser | p.N246S | Q969T7 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NT5C3B | SNV | Missense_Mutation | rs144780012 | c.781N>T | p.Arg261Trp | p.R261W | Q969T7 | protein_coding | deleterious(0.02) | probably_damaging(0.916) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NT5C3B | SNV | Missense_Mutation | novel | c.835N>T | p.Asp279Tyr | p.D279Y | Q969T7 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
NT5C3B | SNV | Missense_Mutation | c.220N>T | p.Arg74Trp | p.R74W | Q969T7 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |